These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Cox G; Louise Jones J; Andi A; Abrams KR; O'Byrne KJ Lung Cancer; 2001 Dec; 34(3):417-26. PubMed ID: 11714539 [TBL] [Abstract][Full Text] [Related]
3. A biological staging model for operable non-small cell lung cancer. Cox G; Jones JL; Andi A; Waller DA; O'Byrne KJ Thorax; 2001 Jul; 56(7):561-6. PubMed ID: 11413356 [TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915 [TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Swinson DE; Jones JL; Richardson D; Cox G; Edwards JG; O'Byrne KJ Lung Cancer; 2002 Sep; 37(3):235-40. PubMed ID: 12234691 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis. Hilbe W; Dirnhofer S; Oberwasserlechner F; Eisterer W; Ammann K; Schmid T; Hilbe G; Thaler J; Wöll E J Clin Pathol; 2003 Oct; 56(10):736-41. PubMed ID: 14514775 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980 [TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Swinson DE; Jones JL; Cox G; Richardson D; Harris AL; O'Byrne KJ Int J Cancer; 2004 Aug; 111(1):43-50. PubMed ID: 15185341 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Tomita M; Matsuzaki Y; Edagawa M; Shimizu T; Hara M; Onitsuka T Eur J Surg Oncol; 2003 Oct; 29(8):654-7. PubMed ID: 14511612 [TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638 [TBL] [Abstract][Full Text] [Related]
12. Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Toomey D; Smyth G; Condron C; Kay E; Conroy R; Foley D; Hong C; Hogan B; Toner S; McCormick P; Broe P; Kelly C; Bouchier-Hayes D Cancer; 2001 Nov; 92(10):2648-57. PubMed ID: 11745200 [TBL] [Abstract][Full Text] [Related]
13. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery. Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571 [TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. Pastorino U; Andreola S; Tagliabue E; Pezzella F; Incarbone M; Sozzi G; Buyse M; Menard S; Pierotti M; Rilke F J Clin Oncol; 1997 Aug; 15(8):2858-65. PubMed ID: 9256129 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162 [TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer]. Wang Y; Zhang XR; Fu J; Tan W; Zhang W Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350 [TBL] [Abstract][Full Text] [Related]